Salvador-Ibarra IJ, Alva-Arroyo NV, Flores-Puente F

Language: Spanish
References: 13
Page: 125-129
PDF size: 442.51 Kb.

ABSTRACT

Introduction. Up to 12% of hospitalised patients with SARS-CoV-2 infection may present with acute myocardial injury such as acute coronary syndrome (ACS), myocarditis, heart failure, hypotension, shock and/or sepsis.
Case report. A 47-year-old male presented with dyspnea, non-specific chest pain, cough, pulse oximetry oxygen saturation (SpO2): 84%. With arterial oxygen pressure/inspired oxygen fraction index (PaO2/ FiO2): 67 mmHg, high-sensitivity cardiac troponin (hs cTn): 5.10 pg/ ml. The patient presented with arterial hypotension: 80/40 mmHg, with control hs cTn 1123 pg/ml. It was decided to perform coronary intervention, finding ectasia of the proximal segment of the anterior descending artery, first diagonal with 50% lesion, 20% lesion of the proximal segment of the right coronary artery.
Discussion. Acute myocardial infarction in patients with COVID-19 should be suspected in the presence of a suggestive clinical picture and an acute increase in hs-cTn greater than the 99th percentile or 5 times its baseline value.

REFERENCES

1. Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM,Masoumi A, et al. Coronavirus disease 2019 (COVID-19)and cardiovascular disease. Circulation 2020; 141:1648–55. doi: 10.1161/CIRCULATIONAHA.120.046941.

2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Yi, et al. Clinicalfeatures of patients infected with 2019 novel coronavirusin Wuhan, China. Lancet. 2020;395(10223):497–506.doi: 10.1016/S0140-6736(20)30183-5.

3. Mattiuzzi C, Lippi G. Which lessons shall we learn fromthe 2019 novel coronavirus outbreak? Ann Transl Med.2020;8(3):48. doi: 10.21037/atm.2020.02.06.

4. Hoffmann M, Kleine-Weber H, Schroeder S, KrügerN, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entrydepends on ACE2 and TMPRSS2 and is blocked by aclinically proven protease inhibitor. Cell. 2020; 181:271–280. doi: 10.1016/j.cell.2020.02.052.

5. Kurz DJ, Eberli FR. Cardiovascular aspects ofCOVID-19. Swiss Med Wkly. 2020.31;150:w20417.DOI: https://doi.org/10.4414/smw.2020.20417.

6. Wu Z, McGoogan JM. Characteristics of and importantlessons from the coronavirus disease 2019 (COVID-19)outbreak in China. JAMA.2020;323:1239–42.doi:10.1001/jama.2020.2648.

7. Siddiqi HK, Libby P, Ridkera PM. COVID-19 – Avascular disease. Trends Cardiovasc Med. 2021;31(1):1–5. doi: 10.1016/j.tcm.2020.10.005.

8. Ye Q, Wang B, Mao J. The pathogenesis and treatmentof the ‘Cytokine Storm′ in COVID-19. J Infect.2020;80:607–613. doi: 10.1016/j.jinf.2020.03.037.

9. Kang Y, Chen T, Mui D, Ferrari V, Jagasia D, Scherrer-Crosbie M, et al. Cardiovascular manifestationsand treatment considerations in COVID-19.Heart. 2020;106(15):1132-141. doi: 10.1136/heartjnl-2020-317056.

10. Klok FA, Kruip MJHA, van der Meer NJM, ArbousMS, Gommers DAMPJ, Kant KM, et al. Incidence ofthrombotic complications in critically ill ICU patientswith COVID-19. Thromb Res 2020;191:145–47. doi:10.1016/j.thromres.2020.04.013.

11. Abdu FA, Mohammed AQ, Liu L, Xu Y, Che W.Myocardial Infarction with Nonobstructive CoronaryArteries (MINOCA): A Review of the CurrentPosition. Cardiology. 2020;145(9):543-552. doi:10.1159/000509100.

12. Manolis AS, Manolis AA, Manolis TA, Melita H.COVID-19 and Acute Myocardial Injury and Infarction:Related Mechanisms and Emerging Challenges. Journalof Cardiovascular Pharmacology and Therapeutics.2021:399-414. doi:10.1177/10742484211011026

13. Fatmi SS, Basso R, Liaqat A, Tariq F, Swamiappan R.COVID-19 Myocarditis: Rationale for Early Diagnosisand Intervention. Cureus. 2021;13(7):e16494. doi:10.7759/cureus.16494.